Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.

Sex Workers, MSM, and Transgender Persons: Disruption in access to PrEP services, reduced capacity for HIV prevention services, , reduced availability of HIV counselling and testing, and disruption in ...

SAN FRANCISCO -- At least 400 researchers, physicians, activists, and other concerned citizens gathered here Monday night to ...

SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...

Prominent gaps in pediatric and adolescent HIV care translate into priorities that need to be addressed for optimizing care ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...